 |
인쇄하기
취소
|
Alvogen Korea to have dominant say at Kunwha
Alvogen Korea, a Korean unit of U.S.-based generic firm Alvogen, will have a dominant say in business decisions at Kunwha Pharma having with 60 billion won in sales, from now on.
A decision by shareholders of Kunwha Thursday sees Alvogen Korea represented by five seats on the Korean company’s seven-member board of directors plus a foreign auditor.
The American company bought a 50.5 perce...
A decision by shareholders of Kunwha Thursday sees Alvogen Korea represented by five seats on the Korean company’s seven-member board of directors plus a foreign auditor.
The American company bought a 50.5 perce...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.